Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989510 | 0.76 | KMT2A (0.70) | MEN1KMT2AMAPTALDH1A1SIGMAR1 | |
| SCHEMBL14155712 | 0.74 | SIGMAR1 (0.42) | KMT2AOPRD1ALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL23040074 | 0.68 | BRD4 (0.48) | MEN1KMT2ABRD4MAPT | |
| SCHEMBL26926615 | 0.68 | BRD4 (0.48) | MEN1KMT2ABRD4MAPT | |
| SCHEMBL14395220 | 0.68 | MAPK1 (0.54) | OPRD1ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL11990426 | 0.68 | MAPK1 (0.54) | OPRD1ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL6852984 | 0.68 | SIGMAR1 (0.51) | OPRD1MAPK1SIGMAR1 | |
| SCHEMBL7260236 | 0.67 | MAPT (0.49) | BRD4MAPTSIGMAR1 | |
| SCHEMBL8069602 | 0.67 | MAPT (0.49) | BRD4MAPTSIGMAR1 | |
| SCHEMBL7261255 | 0.67 | MAPT (0.49) | BRD4MAPTSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450466-B2 | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders | THE GENERAL HOSPTIAL CORPORATION (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110060138-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | THE GENERAL HOSPITAL CORPORATION | 2011-03-10 | — | — | US | disclosed |
| EP-2268647-A2 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | The General Hospital Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060138-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | APP, PSEN1, PSEN2 | MEN1 530/4885KMT2A 2940/4885OPRD1 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.